High levels of deposition of 64Cu-MM-302 and ferumoxytol iron nanoparticles in tumors have been reported to be associated with better treatment outcomes from HER2-targeted PEGylated liposomal doxorubicin and liposomal irinotecan, respectively, in cancer patients (35, 36). Here, ERBB2 is linked to cancer.